RT @herbloong: Our publication on #cost-effectiveness of "PDL-1 Test&Treat Strategy" of #first-line #pembrolizumab for #NSCLC in #hongkong…
RT @herbloong: Our publication on #cost-effectiveness of "PDL-1 Test&Treat Strategy" of #first-line #pembrolizumab for #NSCLC in #hongkong…
RT @herbloong: Our publication on #cost-effectiveness of "PDL-1 Test&Treat Strategy" of #first-line #pembrolizumab for #NSCLC in #hongkong…
RT @herbloong: Our publication on #cost-effectiveness of "PDL-1 Test&Treat Strategy" of #first-line #pembrolizumab for #NSCLC in #hongkong…
RT @herbloong: Our publication on #cost-effectiveness of "PDL-1 Test&Treat Strategy" of #first-line #pembrolizumab for #NSCLC in #hongkong…
RT @herbloong: Our publication on #cost-effectiveness of "PDL-1 Test&Treat Strategy" of #first-line #pembrolizumab for #NSCLC in #hongkong…
Our publication on #cost-effectiveness of "PDL-1 Test&Treat Strategy" of #first-line #pembrolizumab for #NSCLC in #hongkong has been published! Relevant data to help #healthauthorities consider #reimbursement & #funding @CarlosWongHKU #LCSM @CUHKMe
#HealthEconJA Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong https://t.co/7iGhR8NWWl